Novel antibiotics for the treatment of gram-positive bacterial infections

被引:16
|
作者
Brands, M
Endermann, R
Gahlmann, R
Krüger, J
Raddatz, S
Stoltefuss, J
Belov, VN
Nizamov, S
Sokolov, VV
de Meijere, A
机构
[1] Bayer AG, Business Grp Pharma, D-42096 Wuppertal, Germany
[2] Univ Gottingen, Inst Organ Chem, D-37077 Gottingen, Germany
关键词
D O I
10.1021/jm0111191
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The natural dipeptide antibiotic TAN 1057 A,B displays excellent antibacterial activity against staphylococci including methicillin resistant Staphylococcus aureus. However, the in vitro activity against additional Gram-positive strains, in particular pneumococci and Enterococcus faecalis, proved to be considerably lower. We report the synthesis and pharmacological evaluation of new derivatives of this natural product that displayed increased antibacterial potency against staphylococci and were also active against pneumococci. In particular, the analogues bearing modified beta-homoarginine side chains with methylated guanidine moieties were shown to be significantly more potent than the natural product TAN 1057 A,B.
引用
收藏
页码:4246 / 4253
页数:8
相关论文
共 50 条
  • [41] The Relationship of Opportunistic Gram-Positive Bacterial Biofilms and Nosocomial Infections
    Hefni, Hamido M.
    Mohamed, Tarek R.
    Samaha, Hassan A. M.
    Ahmed, Sameh R.
    JOURNAL OF PURE AND APPLIED MICROBIOLOGY, 2015, 9 : 139 - 148
  • [42] Daptomycin therapy for invasive Gram-positive bacterial infections in children
    Ardura, Monica I.
    Mejias, Asuncion
    Katz, Kathy S.
    Revell, Paula
    McCracken, George H., Jr.
    Sanchez, Pablo J.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2007, 26 (12) : 1128 - 1132
  • [43] Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections
    Chien, JW
    Kucia, ML
    Salata, RA
    CLINICAL INFECTIOUS DISEASES, 2000, 30 (01) : 146 - 151
  • [44] Linezolid: Its role in the treatment of gram-positive, drug-resistant bacterial infections
    Ament, PW
    Jamshed, N
    Horne, JP
    AMERICAN FAMILY PHYSICIAN, 2002, 65 (04) : 663 - 670
  • [45] Gram-positive infections: lessons learnt and novel solutions
    Finch, R.
    CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 : 3 - 8
  • [46] Telavancin: a novel lipoglycopeptide for serious Gram-positive infections
    Laohavaleeson, Somvadee
    Kuti, Joseph L.
    Nicolau, David P.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (03) : 347 - 357
  • [47] Novel Therapeutic Agents for Resistant Gram-Positive Infections
    Manfredi, Roberto
    Calza, Leonardo
    CURRENT DRUG THERAPY, 2008, 3 (02) : 98 - 110
  • [48] Clinical relevance of bacteriostatic versus bactericidal activity in the treatment of gram-positive bacterial infections
    Rhee, KY
    Gardiner, DF
    CLINICAL INFECTIOUS DISEASES, 2004, 39 (05) : 755 - 755
  • [49] Pharmacokinetics and preliminary safety of high dose linezolid for the treatment of Gram-positive bacterial infections
    Lopez-Garcia, Belen
    Luque, Sonia
    Roberts, Jason A.
    Grau, Santiago
    JOURNAL OF INFECTION, 2015, 71 (05) : 604 - 607